Literature DB >> 14983493

Gene expression profiling of renal medullary carcinoma: potential clinical relevance.

Ximing J Yang1, Jun Sugimura, Maria S Tretiakova, Kyle Furge, Gregory Zagaja, Mitchell Sokoloff, Michael Pins, Raymond Bergan, David J Grignon, Walter M Stadler, Nicholas J Vogelzang, Bin Tean Teh.   

Abstract

BACKGROUND: Renal medullary carcinoma is a rare kidney tumor with highly aggressive behavior. This tumor occurs exclusively in young patients with sickle cell trait or disease. To the authors' knowledge, very little is known to date regarding the underlying molecular genetics of this tumor, and no effective therapy has been established.
METHODS: The authors analyzed the gene expression profiles of 2 renal medullary carcinomas from patients with sickle cell trait using microarrays containing 21,632 cyclic DNA (cDNA) clones and compared them with the gene expression profiles of 64 renal tumors.
RESULTS: Based on global gene clustering with 3583 selected cDNAs, the authors found a distinct molecular signature of renal medullary carcinoma, which clustered closely with urothelial (transitional cell) carcinoma of the renal pelvis, rather than renal cell carcinoma (RCC). This finding of a significant difference in the gene expression patterns of renal medullary carcinoma compared with RCC suggests that this tumor should not be treated as a conventional RCC but, rather, as a special malignancy. This study also identified genes/proteins that may serve as biomarkers for renal medullary carcinoma or as potential targets of novel therapies. In addition, comparative genomic microarray analysis allowed the authors to predict the lack of chromosomal imbalances in this tumor.
CONCLUSIONS: To the authors' knowledge, the current study is the first molecular profiling of renal medullary carcinoma, a rare but highly aggressive kidney carcinoma. The genes that are expressed specifically in this tumor may lead to not only a better understanding of its molecular pathways and discoveries of novel diagnostic markers but also, more important, to effective therapeutic interventions. Copyright 2004 American Cancer Society.

Entities:  

Mesh:

Year:  2004        PMID: 14983493     DOI: 10.1002/cncr.20049

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Anaplastic renal carcinoma expressing SV40 T antigen in a female TRAMP mouse.

Authors:  Erin M Goodwin; Qing Zhong; Catherine S Abendroth; Lindsay K Ward-Kavanagh; Todd D Schell; Timothy K Cooper
Journal:  Comp Med       Date:  2013-08       Impact factor: 0.982

2.  PRCC-TFE3 renal cell carcinoma in a boy with a history of contralateral mesoblastic nephroma.

Authors:  Ali Mirza Onder; Uygar Teomete; Pedram Argani; Stuart Toledano; Gaston Zilleruelo; Maria M Rodriguez
Journal:  Pediatr Nephrol       Date:  2006-06-29       Impact factor: 3.714

3.  Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy.

Authors:  Peter H O'Donnell; Ana Jensen; Edwin M Posadas; Julia A Bridge; Anjana V Yeldandi; Ximing J Yang; Walter M Stadler; Hikmat Al-Ahmadie
Journal:  Nat Rev Urol       Date:  2010-02       Impact factor: 14.432

4.  Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.

Authors:  Amishi Y Shah; Jose A Karam; Gabriel G Malouf; Priya Rao; Zita D Lim; Eric Jonasch; Lianchun Xiao; Jianjun Gao; Ulka N Vaishampayan; Daniel Y Heng; Elizabeth R Plimack; Elizabeth A Guancial; Chunkit Fung; Stefanie R Lowas; Pheroze Tamboli; Kanishka Sircar; Surena F Matin; W Kimryn Rathmell; Christopher G Wood; Nizar M Tannir
Journal:  BJU Int       Date:  2016-12-09       Impact factor: 5.588

5.  Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature.

Authors:  Roberto Iacovelli; Daniela Modica; Antonella Palazzo; Patrizia Trenta; Gabriele Piesco; Enrico Cortesi
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

Review 6.  Recent developments in the treatment of renal cell carcinoma.

Authors:  Janice P Dutcher
Journal:  Ther Adv Urol       Date:  2013-12

7.  Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy.

Authors:  Roula Albadine; Wenle Wang; Noel A Brownlee; Antoun Toubaji; Athanase Billis; Perdram Argani; Jonathan I Epstein; A Julian Garvin; Rima Cousi; Edward M Schaeffer; Christian Pavlovich; George J Netto
Journal:  J Urol       Date:  2009-06-18       Impact factor: 7.450

8.  VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy?

Authors:  Nathaniel E Smith; Andrea T Deyrup; Adrian Mariño-Enriquez; Jonathan A Fletcher; Julia A Bridge; Peter B Illei; George J Netto; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

9.  Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.

Authors:  Jacob S Lipkin; Syed M Rizvi; Zoran Gatalica; Nabeel E Sarwani; Sheldon L Holder; Mathew Kaag; Joseph J Drabick; Monika Joshi
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

10.  Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, Doxorubicin, and Cisplatin chemotherapy.

Authors:  Ali Imran Amjad; Hira Ali; Leonard J Appleman; Jodi Maranchie; Stephen Jackman; Anil Parwani; Rajiv Dhir; Somak Roy; Rahul A Parikh
Journal:  Case Rep Oncol Med       Date:  2014-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.